HRP20140887T1 - Dijagnoza karcinoma i lijeäśenje, koje se temelji na odc1 genotipu - Google Patents
Dijagnoza karcinoma i lijeäśenje, koje se temelji na odc1 genotipu Download PDFInfo
- Publication number
- HRP20140887T1 HRP20140887T1 HRP20140887AT HRP20140887T HRP20140887T1 HR P20140887 T1 HRP20140887 T1 HR P20140887T1 HR P20140887A T HRP20140887A T HR P20140887AT HR P20140887 T HRP20140887 T HR P20140887T HR P20140887 T1 HRP20140887 T1 HR P20140887T1
- Authority
- HR
- Croatia
- Prior art keywords
- patient
- preparation
- aspirin
- use according
- dfmo
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 4
- 238000003745 diagnosis Methods 0.000 title claims 2
- 201000009030 Carcinoma Diseases 0.000 title 1
- 101100277160 Xenopus laevis odc1-a gene Proteins 0.000 title 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 20
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 20
- VLCYCQAOQCDTCN-ZCFIWIBFSA-N α-difluoromethylornithine Chemical compound NCCC[C@@](N)(C(F)F)C(O)=O VLCYCQAOQCDTCN-ZCFIWIBFSA-N 0.000 claims 13
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims 11
- 229960001138 acetylsalicylic acid Drugs 0.000 claims 11
- 206010009944 Colon cancer Diseases 0.000 claims 5
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- MLKXDPUZXIRXEP-MFOYZWKCSA-N sulindac Chemical compound CC1=C(CC(O)=O)C2=CC(F)=CC=C2\C1=C/C1=CC=C(S(C)=O)C=C1 MLKXDPUZXIRXEP-MFOYZWKCSA-N 0.000 claims 5
- 229960000894 sulindac Drugs 0.000 claims 5
- 108700028369 Alleles Proteins 0.000 claims 4
- 101000585693 Homo sapiens Mitochondrial 2-oxodicarboxylate carrier Proteins 0.000 claims 4
- 101001041245 Homo sapiens Ornithine decarboxylase Proteins 0.000 claims 4
- 102100021079 Ornithine decarboxylase Human genes 0.000 claims 4
- 210000001072 colon Anatomy 0.000 claims 4
- 230000000750 progressive effect Effects 0.000 claims 4
- 108090000623 proteins and genes Proteins 0.000 claims 4
- 238000009109 curative therapy Methods 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000004804 Adenomatous Polyps Diseases 0.000 claims 2
- 206010033109 Ototoxicity Diseases 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 231100000262 ototoxicity Toxicity 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 1
- 206010048832 Colon adenoma Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 201000006107 Familial adenomatous polyposis Diseases 0.000 claims 1
- 230000001594 aberrant effect Effects 0.000 claims 1
- 229960000590 celecoxib Drugs 0.000 claims 1
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 1
- 208000029664 classic familial adenomatous polyposis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- 230000000762 glandular Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 238000002271 resection Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (14)
1. Pripravak koji sadrži α-difluorometilornitin (DFMO) i nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin, za uporabu kod prevencije ili za kurativno liječenje kolorektalnog karcinoma ili njegovih faktora rizika kod pacijenta;
naznačen time da genotip pacijenta na položaju +316 na barem jednom ODC1 alelu promotorskog gena je G; te
naznačen time da liječenje faktora rizika kolorektalnog karcinoma kod pacijenta sprečava stvaranje novih aberantnih kripti crijevnog žljezdanog epitela, novih adenomatoznih polipa ili novih adenoma sa displazijom u pacijentu; proizvoljno pri čemu pacijent je čovjek.
2. Pripravak koji sadrži α-difluorometilornitin (DFMO), za uporabu kod prevencije ili za kurativno liječenje kolorektalnog karcinoma, ili njegovog faktora rizika kako je definirano u zahtjevu 1, kod pacijenta kao što je definirano u zahtjevu 1 naznačen time da se pacijentu također daje pripravak koji sadrži nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin, te se pacijentu daje pripravak koji sadrži nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin prije, istovremeno, ili poslije davanja pripravka koji sadrži DFMO.
3. Pripravak koji sadrži nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin, za uporabu kod prevencije ili za kurativno liječenje kolorektalnog karcinoma, ili njegovog faktora rizika kako je definirano u zahtjevu 1, kod pacijenta kao što je definirano u zahtjevu 1 naznačen time da se pacijentu također daje pripravak koji sadrži α-difluorometilornitin (DFMO), te se pacijentu daje pripravak koji sadrži DFMO prije, istovremeno, ili poslije davanja pripravka koji sadrži nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin.
4. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time da se genotip pacijenta određuje primanjem izvješća koje sadrži navedeni genotip ili uzimanjem anamneze pacijenta koja otkriva rezultate; ili određivanjem nukleotidne baze na položaju +316 za jedan alel za ODC1 promotorski gen pacijenta; ili određivanjem nukleotidnih baza na položaju +316 za oba alela za ODC1 promotorski gen pacijenta.
5. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-3, naznačen time da genotip pacijenta na položaju +316 za oba alela za ODC1 promotorski gen je GG ili GA.
6. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-5, naznačen time da, prije određivanja genotipa pacijenta, pacijent je već bio liječen sa pripravkom koji sadrži DMFO i/ili nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin, ali u nižoj dozi od DMFO i/ili ne-steroidnog protuupalnog lijeka (NSAID) koji sadrži ne-aspirin.
7. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-6, naznačen time da je nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin odabran iz skupine koju čine selektivni inhibitor COX-2, sulindac i celekoksib.
8. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time da nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin je sulindac, te pri čemu
(i) DFMO se daje oralno, proizvoljno pri čemu je učinkovita količina DFMO 500 mg/dan;
(ii) DFMO se daje intravenozno, proizvoljno pri čemu je učinkovita količina DFMO od 0.05 do 5.0 g/m2/dan; ili
(iii) te se DFMO daje najmanje drugi puta.
9. Pripravak za uporabu prema bilo kojem patentnom zahtjevu 1-7, naznačen time da nesteroidni protuupalni lijek (NSAID) koji sadrži ne-aspirin je sulindac, te pri čemu je učinkovita količina sulindaca od 10 do 1500 mg/dan, kao što je od 10 do 400 mg/dan, ili kao 150 mg/dan; ili pri čemu se sulindac daje najmanje drugi puta.
10. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-7, naznačen time da navedeni pacijent ima solidni tumor, te je solidni tumor reseciran.
11. Pripravak za uporabu prema bilo kojem od patentnih zahtjeva 1-10, naznačen time da je kolorektalni karcinom u fazi I, ili fazi II, ili fazi III, ili fazi IV.
12. Pripravak za uporabu prema bilo kojem patentnom zahtjevu 1-11, naznačen time da tretman sprečava stvaranje novih napredujućih neoplazmi debelog crijeva (npr. nove napredujuće neoplazme desne strane debelog crijeva ili nove napredujuće neoplazme lijeve strane debelog crijeva) kod pacijenta, ili tretman sprečava ototoksičnost ili rizik za ototoksičnost kod pacijenta.
13. Pripravak za uporabu prema bilo kojem patentnom zahtjevu 1-12, naznačen time da pacijent je identificiran da ima -
(i) jedan ili više adenomatoznih polipa u debelom crijevu, rektumu ili slijepom crijevu;
(ii) jedan ili više napredujućih neoplazmi debelog crijeva; ili
(iv) dijagnozu obiteljske adenomatozne polipoze.
14. Pripravak za uporabu prema bilo kojem patentnom zahtjevu 1-13, naznačen time da pacijent ima povijest resekcije jednog ili više adenoma debelog crijeva.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21621609P | 2009-05-14 | 2009-05-14 | |
| US21768209P | 2009-06-03 | 2009-06-03 | |
| US21767909P | 2009-06-03 | 2009-06-03 | |
| PCT/US2010/034974 WO2010132817A1 (en) | 2009-05-14 | 2010-05-14 | Carcinoma diagnosis and treatments, based on odc1 genotype |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20140887T1 true HRP20140887T1 (hr) | 2014-11-21 |
Family
ID=43085356
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20140887AT HRP20140887T1 (hr) | 2009-05-14 | 2014-09-17 | Dijagnoza karcinoma i lijeäśenje, koje se temelji na odc1 genotipu |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US8329636B2 (hr) |
| EP (1) | EP2430452B1 (hr) |
| JP (2) | JP6083860B2 (hr) |
| CN (1) | CN102483415B (hr) |
| AU (1) | AU2010248803B2 (hr) |
| CA (1) | CA2761946A1 (hr) |
| DK (1) | DK2430452T3 (hr) |
| ES (1) | ES2507145T3 (hr) |
| HK (1) | HK1171082A1 (hr) |
| HR (1) | HRP20140887T1 (hr) |
| IL (1) | IL216369B (hr) |
| PL (1) | PL2430452T3 (hr) |
| PT (1) | PT2430452E (hr) |
| SI (1) | SI2430452T1 (hr) |
| SM (1) | SMT201400177B (hr) |
| WO (1) | WO2010132817A1 (hr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010132817A1 (en) | 2009-05-14 | 2010-11-18 | Cancer Prevention Pharmaceuticals, Llc | Carcinoma diagnosis and treatments, based on odc1 genotype |
| JP6083646B2 (ja) * | 2010-05-14 | 2017-02-22 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ａｒｉｚｏｎａ | 食事性ポリアミン含量に基づく癌予防及び治療法 |
| WO2012088146A2 (en) * | 2010-12-20 | 2012-06-28 | The University Of Notre Dame | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease |
| US20120172244A1 (en) | 2010-12-20 | 2012-07-05 | Steven Buechler | Biomarkers and uses thereof in prognosis and treatment strategies for right-side colon cancer disease and left-side colon cancer disease |
| DK2912193T3 (en) | 2012-10-29 | 2018-12-03 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | PREDICTIVE MARKERS FOR POLYAMINE INHIBITOR CANCER THERAPIES |
| US10655183B2 (en) | 2014-06-18 | 2020-05-19 | Arizona Board Of Regents On Behalf Of University Of Arizona | Carcinoma diagnosis and treatment based on ODC1 genotype |
| EP3256117A4 (en) * | 2015-02-12 | 2018-10-10 | The Arizona Board of Regents on behalf of The University of Arizona | Methods for treating neuroblastoma |
| CA2980078C (en) * | 2015-03-16 | 2024-03-12 | Personal Genome Diagnostics Inc. | Systems and methods for analyzing nucleic acid |
| WO2017075576A1 (en) | 2015-10-30 | 2017-05-04 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
| MA43114A (fr) | 2015-10-30 | 2018-09-05 | Cancer Prevention Pharmaceuticals Inc | Formulation combinée à dose fixe d'éflornithine et sulindac |
| JP6963271B2 (ja) * | 2017-01-20 | 2021-11-05 | 国立大学法人東海国立大学機構 | イヌの遺伝性消化管腫瘍症の遺伝子診断法 |
| WO2020236562A1 (en) | 2019-05-17 | 2020-11-26 | Cancer Prevention Pharmaceuticals, Inc. | Methods for treating familial adenomatous polyposis |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3654349A (en) | 1970-05-01 | 1972-04-04 | Merck & Co Inc | Substituted indenyl acetic acids |
| US3647858A (en) | 1970-05-01 | 1972-03-07 | Merck & Co Inc | Process for preparing 1-benzylidene-3-indenyl acetic acids |
| US4413141A (en) | 1977-07-11 | 1983-11-01 | Merrell Toraude Et Compagnie | 2-(Difluoromethyl)-2,5-diaminopentanoic acid |
| US4330559A (en) * | 1977-07-11 | 1982-05-18 | Merrell-Toraude Et Cie | Method of treating benign prostatic hypertrophy |
| WO1982001011A1 (en) | 1980-09-24 | 1982-04-01 | Corp Cetus | Diagnostic method and probe |
| EP0084796B1 (en) | 1982-01-22 | 1990-05-02 | Cetus Corporation | Hla typing method and cdna probes used therein |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US4683194A (en) | 1984-05-29 | 1987-07-28 | Cetus Corporation | Method for detection of polymorphic restriction sites and nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4859452A (en) | 1986-01-17 | 1989-08-22 | Board Of Regents, The University Of Texas System | Methods for the reduction of difluoromethylornithine associated toxicity |
| CA1284931C (en) | 1986-03-13 | 1991-06-18 | Henry A. Erlich | Process for detecting specific nucleotide variations and genetic polymorphisms present in nucleic acids |
| US4925835A (en) | 1986-05-01 | 1990-05-15 | Sloan-Kettering Institute For Cancer Research | Aziridinyl putrescine containing compositions and their uses in treating prostate cancer |
| US5002879A (en) | 1986-05-06 | 1991-03-26 | Merrell Dow Pharmaceuticals | Treatment of tumors with autologous LAK cells, interleukin-2 and an ornithine decarboxylase inhibitor |
| CA1338457C (en) | 1986-08-22 | 1996-07-16 | Henry A. Erlich | Purified thermostable enzyme |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| FR2706255B1 (fr) | 1993-06-17 | 1995-10-27 | Univ Rennes | Composition à usage alimentaire et/ou pharmaceutique pauvre en polyamines et applications thérapeutiques. |
| DE69531542T2 (de) | 1994-02-07 | 2004-06-24 | Beckman Coulter, Inc., Fullerton | Ligase/polymerase-vermittelte analyse genetischer elemente von einzelnukleotid-polymorphismen und ihre verwendung in der genetischen analyse |
| US5843929A (en) | 1996-03-22 | 1998-12-01 | Mayo Foundation For Medical Education And Research | Chemoprevention of metachronous adenomatous colorectal polyps |
| AU754864B2 (en) * | 1998-03-28 | 2002-11-28 | Arizona Board Of Regents On Behalf Of The University Of Arizona, The | DFMO and sulindac combination in cancer chemoprevention |
| US7700568B2 (en) * | 1998-06-30 | 2010-04-20 | Sloan-Kettering Institute For Cancer Research | Uses of DNA-PK |
| DE69930764D1 (de) * | 1998-12-23 | 2006-05-18 | G D Searle Llc St Louis | Verwendung von cyclooxygenase-2 inhibitor celecoxib und capecitabine zur kombinationsbehandlung von neoplasia |
| US6753422B2 (en) | 1999-03-01 | 2004-06-22 | O'brien Thomas G. | Odc allelic analysis method for assessing carcinogenic susceptibility |
| CA2373931A1 (en) | 1999-05-17 | 2000-11-23 | Richard Love | Dfmo and celecoxib in combination for cancer chemoprevention and therapy |
| US6602910B2 (en) | 2000-03-07 | 2003-08-05 | Ilex Oncology, Inc. | D-enantiomer of DFMO and methods of use therefor |
| WO2001068076A2 (en) | 2000-03-07 | 2001-09-20 | Ilex Oncology, Inc. | D-enantiomer of dfmo and methods of use thereof for treating cancer |
| EP1351675A2 (en) | 2000-08-24 | 2003-10-15 | The Regents of the University of California | Alpha-difluoromethylornithine (dfmo) use in the human prostate |
| US7211602B2 (en) | 2001-11-16 | 2007-05-01 | Als Therapy Development Foundation, Inc. | Treatment of neurodegenerative disorders through the modulation of the polyamine pathway |
| US9072778B2 (en) | 2005-12-20 | 2015-07-07 | University Of Hawaii | Treatment regimen for N-MYC, c-MYC, and L-MYC amplified and overexpressed tumors |
| WO2009048932A2 (en) | 2007-10-09 | 2009-04-16 | Children's Medical Center Corporation | Methods to regulate mirna processing by targeting lin-28 |
| US20100291165A1 (en) | 2008-12-08 | 2010-11-18 | Glenn Jr Robert Wayne | Personal care composition in the form of an article having a hydrophobic surface-resident coating |
| WO2010132817A1 (en) | 2009-05-14 | 2010-11-18 | Cancer Prevention Pharmaceuticals, Llc | Carcinoma diagnosis and treatments, based on odc1 genotype |
| JP6083646B2 (ja) | 2010-05-14 | 2017-02-22 | アリゾナ ボード オブ リージェンツ オン ビハーフ オブ ザ ユニバーシティー オブ アリゾナＡｒｉｚｏｎａ Ｂｏａｒｄ ｏｆ Ｒｅｇｅｎｔｓ ｏｎ ｂｅｈａｌｆ ｏｆ ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ ｏｆ Ａｒｉｚｏｎａ | 食事性ポリアミン含量に基づく癌予防及び治療法 |
| DK2912193T3 (en) | 2012-10-29 | 2018-12-03 | Arizona Board Of Regents On Behalf Of Univ Of Arizona | PREDICTIVE MARKERS FOR POLYAMINE INHIBITOR CANCER THERAPIES |
-
2010
- 2010-05-14 WO PCT/US2010/034974 patent/WO2010132817A1/en active Application Filing
- 2010-05-14 DK DK10775626.4T patent/DK2430452T3/da active
- 2010-05-14 PL PL10775626T patent/PL2430452T3/pl unknown
- 2010-05-14 JP JP2012511052A patent/JP6083860B2/ja not_active Expired - Fee Related
- 2010-05-14 PT PT107756264T patent/PT2430452E/pt unknown
- 2010-05-14 ES ES10775626.4T patent/ES2507145T3/es active Active
- 2010-05-14 US US12/780,592 patent/US8329636B2/en active Active
- 2010-05-14 AU AU2010248803A patent/AU2010248803B2/en not_active Ceased
- 2010-05-14 SI SI201030738T patent/SI2430452T1/sl unknown
- 2010-05-14 EP EP10775626.4A patent/EP2430452B1/en active Active
- 2010-05-14 CA CA2761946A patent/CA2761946A1/en not_active Abandoned
- 2010-05-14 CN CN201080031983.5A patent/CN102483415B/zh not_active Expired - Fee Related
-
2011
- 2011-11-14 IL IL216369A patent/IL216369B/en active IP Right Grant
-
2012
- 2012-11-19 HK HK12111787.0A patent/HK1171082A1/xx not_active IP Right Cessation
- 2012-12-10 US US13/709,753 patent/US9121852B2/en active Active
-
2014
- 2014-09-17 HR HRP20140887AT patent/HRP20140887T1/hr unknown
- 2014-11-21 SM SM201400177T patent/SMT201400177B/xx unknown
-
2015
- 2015-09-01 US US14/841,750 patent/US9937141B2/en active Active
- 2015-10-29 JP JP2015213116A patent/JP2016074672A/ja active Pending
-
2018
- 2018-02-23 US US15/904,153 patent/US20190038584A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010248803B2 (en) | 2014-05-29 |
| US20100317708A1 (en) | 2010-12-16 |
| US8329636B2 (en) | 2012-12-11 |
| IL216369B (en) | 2018-07-31 |
| CN102483415A (zh) | 2012-05-30 |
| HK1171082A1 (en) | 2013-03-15 |
| IL216369A0 (en) | 2012-01-31 |
| EP2430452A1 (en) | 2012-03-21 |
| US9937141B2 (en) | 2018-04-10 |
| ES2507145T3 (es) | 2014-10-14 |
| JP2016074672A (ja) | 2016-05-12 |
| SI2430452T1 (sl) | 2014-11-28 |
| US20160213634A1 (en) | 2016-07-28 |
| AU2010248803A1 (en) | 2011-12-01 |
| PL2430452T3 (pl) | 2014-12-31 |
| EP2430452A4 (en) | 2013-03-06 |
| WO2010132817A1 (en) | 2010-11-18 |
| JP2012526852A (ja) | 2012-11-01 |
| US20190038584A1 (en) | 2019-02-07 |
| SMT201400177B (it) | 2015-01-15 |
| CN102483415B (zh) | 2015-09-09 |
| US9121852B2 (en) | 2015-09-01 |
| CA2761946A1 (en) | 2010-11-18 |
| US20130164751A1 (en) | 2013-06-27 |
| JP6083860B2 (ja) | 2017-02-22 |
| PT2430452E (pt) | 2014-09-30 |
| EP2430452B1 (en) | 2014-06-25 |
| DK2430452T3 (da) | 2014-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20140887T1 (hr) | Dijagnoza karcinoma i lijeäśenje, koje se temelji na odc1 genotipu | |
| Toden et al. | Novel evidence for curcumin and boswellic acid–induced chemoprevention through regulation of miR-34a and miR-27a in colorectal cancer | |
| Javadinia et al. | Therapeutic potential of targeting the Wnt/β‐catenin pathway in the treatment of pancreatic cancer | |
| Zhao et al. | Ursolic acid suppresses colorectal cancer by down-regulation of Wnt/β-catenin signaling pathway activity | |
| Rastogi et al. | (6)-Gingerolinduced myeloid leukemia cell death is initiated by reactive oxygen species and activation of miR-27b expression | |
| Bayati et al. | Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt/p53 axis in pre-B acute lymphoblastic leukemia cells | |
| Quan et al. | Inhibition of autophagy enhances the anticancer effect of enzalutamide on bladder cancer | |
| Shehatta et al. | Baicalin; a promising chemopreventive agent, enhances the antitumor effect of 5-FU against breast cancer and inhibits tumor growth and angiogenesis in Ehrlich solid tumor | |
| Warusavitarne et al. | The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer | |
| JP2012526852A5 (hr) | ||
| Huang et al. | The CCR5 antagonist maraviroc causes remission of pancreatic cancer liver metastasis in nude rats based on cell cycle inhibition and apoptosis induction | |
| Sharma et al. | Role of Hedgehog and Hippo signaling pathways in cancer: a special focus on non-coding RNAs | |
| Sherif et al. | Hepatoprotective effect of Ginkgo biloba extract against methotrexate-induced hepatotoxicity via targeting STAT3/miRNA-21 axis | |
| Krajewska et al. | One step ahead: miRNA-34 in colon cancer-future diagnostic and therapeutic tool? | |
| Szylberg et al. | Large bowel genetic background and inflammatory processes in carcinogenesis–systematic review | |
| Zhang et al. | Sanguisorba officinalis L. suppresses 5-fluorouracil-sensitive and-resistant colorectal cancer growth and metastasis via inhibition of the Wnt/β-catenin pathway | |
| Wambecke et al. | The influence of long non-coding RNAs on the response to chemotherapy in ovarian cancer | |
| Kozak et al. | Novel targets in pancreatic cancer research | |
| Mohammadian et al. | Stattic enhances the anti-proliferative effect of docetaxel via the Bax/Bcl-2/cyclin B axis in human cancer cells | |
| Wang et al. | The emerging roles and therapeutic implications of epigenetic modifications in ovarian cancer | |
| Liu et al. | Enhancement of cisplatin cytotoxicity by Retigeric acid B involves blocking DNA repair and activating DR5 in prostate cancer cells | |
| Liegl et al. | Immunohistochemical and mutational analysis of PDGF and PDGFR in desmoid tumours: is there a role for tyrosine kinase inhibitors in c‐kit‐negative desmoid tumours? | |
| El-Shemi et al. | Paricalcitol enhances the chemopreventive efficacy of 5-fluorouracil on an intermediate-term model of azoxymethane-induced colorectal tumors in rats | |
| Varol et al. | The epigenetically regulated effects of Wnt antagonists on the expression of genes in the apoptosis pathway in human bladder cancer cell line (T24) | |
| Al Moubarak et al. | Curcumin-Polyallyhydrocarbon nanocapsules potently suppress 1, 2-dimethylhydrazine-induced colorectal cancer in mice by inhibiting Wnt/β-catenin pathway |